New Cancer Research Shows Promise in Blood Cancer, Prostate Cancer, and Ovarian Cancer Treatment

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial. The study results offer hope to BPDCN patients with limited treatment options, and the positive results suggest that PVEK should be considered a potential standard treatment for BPDCN patients.

Metastasis-directed therapy significantly improved outcomes in patients with oligometastatic prostate cancer, according to a first-of-its-kind meta-analysis evaluating the addition of metastasis-directed radiation therapy to standard-of-care treatment. Gathering level one evidence of the benefits of MDT in this cancer type has been a challenge due to several factors. Most significant among them are that only a small number of patients have oligometastatic cancer - meaning they have multiple metastases but not enough to be considered widely metastatic - and the relative indolence of oligometastatic disease. By bringing together all available patient data from randomized clinical trials, the meta-analysis provided evidence that MDT improves patient outcomes.

A new study published in Science Translational Medicine suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better. PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with impaired DNA repair. However, many tumors eventually stop responding, even when the drugs initially show results.

Researchers found that ovarian cancer cells rapidly activate a pro-survival program after exposure to PARP inhibitors. A key driver of this response is FRA1, a transcription factor that helps turn on genes that allow cancer cells to adapt and avoid cell death. The research team tested whether brigatinib, an FDA-approved drug currently used to treat certain lung cancers, could block this survival response and enhance the effects of PARP inhibitors. Brigatinib was selected because of its ability to inhibit multiple signaling pathways involved in cancer cell survival.

The results showed that combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Importantly, this effect was seen only in cancer cells, not in normal cells, suggesting the potential for a more targeted and safer treatment approach. The researchers discovered that brigatinib helps in a completely new way. Rather than acting through traditional DNA repair pathways, brigatinib shuts down two key signaling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on to survive. Blocking both signals at once weakened the cancer cells' ability to adapt and resist treatment, leaving them far more vulnerable to PARP inhibitors.

The researchers also found a potential clue for identifying which patients might benefit most from this treatment. Tumors with higher levels of the signaling molecules FAK and EPHA2 responded better to the drug combination. Other data suggest that ovarian cancers with high levels of these molecules are often more aggressive, highlighting the promise of this approach for harder-to-treat cases.

In breast cancer research, investigators identified a targetable driver of brain metastases in patients with aggressive inflammatory breast cancer. The study uncovers a novel role for soluble E-cadherin (sEcad) in promoting tumor invasion while resisting cancer cell death and triggering brain inflammation via the CXCR2 signaling pathway. The results suggest that targeting sEcad or the CXCR2 pathway could treat or prevent brain metastasis. This readily measurable blood biomarker plays a key role in driving brain metastasis, and targeting this pathway has tremendous potential to treat and prevent this serious complication and could help guide future therapies.

American women now have the option of screening for cervical cancer at home, using newly approved self-collection tools. While experts hope this will increase uptake in the under-screened population, a study published in JAMA Network Open found the majority (60.8%) still prefer to see a medical professional in-clinic. The study also revealed that marginalized populations were more likely to prefer at-home self-sampling, and women with low income and those who do not trust the health care system were more likely to be uncertain about which option to choose. Of 2,300 screening-eligible women, just 20.4% prefer to screen for cervical cancer at home, and 18.8% were unsure about their choice.

Observers note a significant acceleration in the adoption of circulating tumor DNA analysis and tumor genomics among general oncology practitioners. This genomic insight is driving treatment decisions across various tumor types, moving beyond traditional academic settings. Protocols based on findings like ESR1 or PI3K mutations are anticipated to undergo substantial revision in the near future. The imperative for continuous data assimilation applies universally to both academic and community-based physicians to ensure optimal patient care pathways.